Carmel Valley-based Evoke Pharma Inc. recently registered for an initial public offering of stock. The company said in its Securities and Exchange Commission filing that it hopes to raise as much as $23 million.

The stock has not yet been priced. The firm applied to list its stock on the Nasdaq under the symbol EVOK.

Evoke specializes in drugs to treat gastrointestinal disorders and diseases. EVK-001 is a nasal spray used to treat diabetic gastroparesis. The company said it plans to start a phase 3 trial on the compound during the second half of 2013.

— SDBJ Staff Report